Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An ongoing series of studies is assessing the pharmacokinetics and safety of triple artemisinin combinations (TACTs). The most important finding to date – which allowed the multinational clinical trials to proceed – was to show that mefloquine did not potentiate the effects of piperaquine on ventricular repolarisation. An assessment of the interaction between artemether-lumefantrine and amodiaquine is in progress.